In his bookTiHKAL (Tryptamines I Have Known and Loved) and other publications,Alexander Shulgin reported thedose of 5-MeO-DiPT to be 6 to 12mgorally, itsonset to be 20 to 30minutes or within 1hour, its time to peak effects to be 1 to 1.5hours, and itsduration to be 4 to 8hours.[1][2][23][24][8][4] However, in other publications besidesTiHKAL he gave a dose range of 6 to 10mg[2][8] or a dose range of 8 to 12mg.[23][24][8] According to Shulgin, testing of 5-MeO-DiPT started at a dose of 0.1 mg and gradually titrated up in 10 human volunteers, with threshold effects occurring at a dose of 4mg orally and full effects occurring at doses of 6mg or more.[2][8] The drug's has been described as "fast-acting" and its duration has also been reported to be "short-lived" and as brief as 3 to 6hours.[1][2][7][8][4] In addition to oral administration, 5-MeO-DiPT has been reported to be used less commonly bysmoking,insufflation, orintravenous injection.[4][3][5] Forms known to be used includepowder,tablets, andcapsules.[4]
Thepsychedelic orperceptual effects of 5-MeO-DiPT have been reported to include colors on edges of eyesight, color contrasts and sparkle, altered facial perception,sensory distortion, few if anyvisual enhancements, someclosed-eye imagery but only at high doses, feelings of strangeness, objects having special significance, somemusicalsound distortions reminiscent of those ofDiPT,music sounding strange and fake,time dilation, having only mildhallucinogenic effects, outgoing rather than inwardly reflective intellectual activation, lack ofintuitive leaps, and a wave-like experience wherein the effects "waved in and out".[1][2][7][4][8] Affective and behavioral effects have includedstimulation, someentactogen-like effects,talkativeness,disinhibition, emotional enhancement, opening of affect, easy emotional expression, easy communication with others, reduced guards and reservations,relaxation, feeling happy, mildeuphoria, and mellowness.[1][2][7][4][8] In addition, the drug has been reported to produce tactile or sensual enhancement, one's body feeling alive and alert, feeling like waves are passing back and forth over one's body, awareness of vibrations, feelingsexually aroused, and "dramatic"erotic or sexual enhancement.[1][2][7][4][8]
5-MeO-DiPT has been described asLSD-like in some ways but as being quite different from other psychedelics.[1][2][7] Descriptions have included the drug never being psychedelic in the way of classical psychedelics like LSD andpsilocybin, there being an absence of intensesensory disturbances or hallucinogenic effects as with other psychedelics likedimethyltryptamine (DMT) and psilocybin, never feeling as though one was having apsychedelic experience, and being able to function normally on a social level including at public events even at high doses.[1][2][7] However, one user who took a high dose described reaching a "plus-three" on theShulgin Rating Scale in a very LSD-like manner but without the visuals.[1] Higher doses may produce more psychedelic effects, but the drug is still described as not that psychedelic even at such doses.[7] Despite its lack of robust hallucinogenic effects at typical doses, 5-MeO-DiPT is described as nonetheless producing quite profound emotional and intellectual modifications.[2]
5-MeO-DiPT is reported to differ in its subjective effects from thestructurally related DiPT in most respects but to share someauditory effects with this drug.[2][1] In terms of these effects, whereas DiPT causedharmonic distortion of heard sounds, 5-MeO-DiPT caused changes in musical character and interpretation without apparent changes in harmonic structure.[1] As such, while both produced auditory effects, DiPT and 5-MeO-DiPT caused different distortions of musical interpretation.[1] 5-MeO-DiPT has been described as a "psychedelicstimulant" and has a reputation as a "sexual enhancer" or "aphrodisiac".[7][4] Among its effects, the pro-sexual effects of 5-MeO-DiPT have been especially highlighted, with these effects being present at low doses.[1] Users have remarked that it took them to a "marvelous sexy place", that "everything [was] shaded with eroticism", that the "erotic world was fantastic, explosive, almost scary", and that the drug may vie with2C-B as a sexual enhancer or that it left 2C-B "in the dust" in this regard.[1][7]
5-MeO-DiPT has been described as having effects similar to those of5-MeO-MiPT and these drugs as having unique and distinct effects from those of other psychedelic tryptamines.[7][22] They are reported to be very pro-sexual, much more stimulant, and more likeparty drugs than other tryptamines.[7][3][22] While 5-MeO-DiPT and 5-MeO-MiPT are described as pro-sexual, they may not be innately aphrodisiac but instead may produce tactile enhancement in a way that lends itself to sex.[7] The tactile enhancement and "body high" with 5-MeO-DiPT and 5-MeO-MiPT may in part be why they have been compared to entactogens likeMDMA.[7] 5-MeO-DiPT has been described as being closer to MDMA in its effects than to psychedelic tryptamines and that the effects are a "body high kind of thing".[7] The drug is also known to be combined with other drugs such as MDMA.[25]
Notes: The smaller the value, the more avidly the drug interacts with the site. All proteins are human unless otherwise specified.Refs:[35][36][9][10][37][38] [11][39][12][13][40]
In addition to its directserotonin receptor interactions, 5-MeO-DiPT is aserotonin reuptake inhibitor with potency ranging from similar to its serotonin 5-HT2A receptor agonism to very low in different studies.[12][41][42][13] Conversely, it does not significantly affectdopamine ornorepinephrinereuptake and shows no activity as amonoamine releasing agent.[11][13][43][39][42] The drug can block the serotonin release induced bymethamphetaminein vitro.[43][42] 5-MeO-DiPT can elevate brain serotonin levels in rodents, presumably via its serotonin reuptake inhibition.[25][44] The elevations in serotonin levels caused by 5-MeO-DiPT may be limited by its concomitant serotonin 5-HT1A receptor agonism, as serotonin 5-HT1A receptors serve asinhibitoryautoreceptors that limit serotonin release.[41] By an unknown mechanism, but possibly serotonin 5-HT2A receptor agonism, 5-MeO-DiPT may also elevate braindopamine levels in rodents, including in theprefrontal cortex,striatum, and/ornucleus accumbens, although findings are mixed.[25][41][44] Themechanism of action of thepsychedelic effects of 5-MeO-DiPT is thought to be serotonin 5-HT2A receptor agonism, but its full mechanism of action is unclear and additional mechanisms may also be involved.[43][37][39]
5-MeO-DiPT produces thehead-twitch response, a behavioral proxy ofpsychedelic-like effects, in rodents.[45][26][3][46][13][47][37] As with many other psychedelics, this follows aninverted U-shapeddose–response curve.[46][37] The head-twitch response induced by 5-MeO-DiPT is blocked by serotonin 5-HT2A receptorantagonists such asvolinanserin.[46][37] 5-MeO-DiPT's head-twitch response is described as robust but also weak and much lower in magnitude than that produced by other serotonergic psychedelics such as5-MeO-DMT orDOM.[38][37][13] The serotonin 5-HT1A receptor agonism of 5-MeO-DiPT may inhibit its serotonin 5-HT2A receptor-mediated head-twitch response.[37] 5-MeO-DiPT partially substitutes forLSD in rodentdrug discrimination tests, with 52% responding at 1mg/kg, 75% responding at 3mg/kg, and behavioral disruption at higher doses.[37] In addition, it substitutes for DOM in rodent drug discrimination tests.[37][48] The stimulus properties of 5-MeO-DiPT in LSD substitution tests are completely and insurmountably blocked by the serotonin 5-HT2A receptor antagonist volinanserin.[38][37] Conversely, they are partially and surmountably blocked by the serotonin 5-HT1A receptor antagonistWAY-100635.[38][37] Besides psychedelic-like effects, 5-MeO-DiPT also produceshypolocomotion andhypothermia in rodents and potentiates the forepaw treading induced by the serotonin 5-HT1A receptor agonist8-OH-DPAT.[13][47][49][25]
4-MeO-DiPT, 6-MeO-DiPT, and 7-MeO-DiPT are knownpositional isomers of 5-MeO-DiPT.[1][24] 6-MeO-DiPT and 7-MeO-DiPT have been described byAlexander Shulgin as being inactive at doses of up to 50mg and 70mgorally, respectively, whereas 4-MeO-DiPT was not assessed.[1][24]
5-MeO-DiPT was discovered in the 1970s and was first described byAlexander Shulgin and Michael Carter in 1980.[7][16][1][2] Shulgin tested it and discovered its effects starting in 1975.[58][59] The drug started to be encountered as a novelrecreational anddesigner drug in 1999.[3][4] 5-MeO-DiPT became a temporarilycontrolled substance in theUnited States in 2003 and a permanently controlled substance in 2004.[3][18][19] Therecreational use of 5-MeO-DiPT appears to have declined over time and its use is described as being not very prevalent.[4][7][3]
Sveriges riksdags health ministryStatens folkhälsoinstitut classified 5-MeO-DiPT as "health hazard" under the actLagen om förbud mot vissa hälsofarliga varor (translatedAct on the Prohibition of Certain Goods Dangerous to Health) as of Oct 1, 2004, in their regulation SFS 2004:696 listed as 5-metoxi-N,N-diisopropyltryptamin (5-MeO-DIPT), making it illegal to sell or possess.[66]
On April 4, 2003, theUnited StatesDEA added both 5-MeO-DiPT andα-methyltryptamine (AMT) to Schedule I of theControlled Substances Act under "emergency scheduling" procedures.[3] The drugs were officially placed into Schedule I on September 29, 2004.[3] Prior to its prohibition in the U.S., 5-MeO-DiPT was sold online alongside psychoactive analogues such asdiisopropyltryptamine (DiPT), anddipropyltryptamine (DPT), neither of which have yet been expressly outlawed.
^abcdefghijklmnopqrstuvwPalamar JJ, Acosta P (January 2020)."A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamines".Hum Psychopharmacol.35 (1) e2719.doi:10.1002/hup.2719.PMC6995261.PMID31909513.Other 5-MeO compounds 5-MeO compounds were less prevalent in this sample of experienced tryptamine users. We received few comments about the effects of individual compounds in this subclass, and these compounds tended to be described as being more sexual than other compounds. One participant also pointed out that 5-Meo-DIPT ("Foxy Methoxy" or "Foxy") gained notoriety in the United States as a sexual enhancement drug. 5-Meo-DIPT, Foxy, or Moxy (5-Meo-MIPT) are tryptamines that are distinct. A lot of people I know that like them think they're very aphrodisiac and much more stimulant and a party drug. My opinion on 5-MeO-MIPT is that it was a very sexual chemical … it feels good to touch things, and that sort of sensation certainly lends itself to sex but I wouldn't call it innately an aphrodisiac. These increased sensations of touch are likely why some users compared the "body high" with the high associated with MDMA use. The effects of 5-MeO compounds were also described as being shorter lasting than other tryptamines. I would actually say that it is closer to MDMA in its effects. The whole series of 5-MeO and 4-MeO … they're both very closely related in their effects so it tends to be a body high kind of thing. At higher doses it can get more psychedelic, but it's not that psychedelic. [...] first discovered or first synthesized as early as [...] in the 1970s (e.g., 4-HO-MET and 5-MeO-DIPT). However, use does not appear to be very prevalent (Palamar & Le, 2019; Palamar, Martins, Su, & Ompad, 2015), and most of these compounds do not have much of a presence in the published literature. [...] Finally, 5-MeO-DIPT ("Foxy") was also used by a few of our participants, and they noted sexual effects of the drug. Although sometimes described as a sex drug on the internet, academic literature does not seem to describe sexual effects of the drug. However, multiple studies in Asia have linked use of 5-MeO-DIPT to increased risk for HIV diagnosis, likely due to risky sexual behavior involving the drug (Hayashi, Wakabayashi, Ikushima, & Tarui, 2017; Kuwahara et al., 2008; Shan et al., 2018).
^abcdefghijklmMeatherall R, Sharma P (2003). "Foxy, a designer tryptamine hallucinogen".J Anal Toxicol.27 (5):313–317.doi:10.1093/jat/27.5.313.PMID12908946.Foxy is slang for 5-methoxy-N,N-diisopropyltryptamine. It has hallucinogenic properties, similar to other tryptamine compounds, and is mildly euphoric. [...] This case report describes a 21-year-old Caucasian man who ingested a pill called Foxy containing an unknown amount of drug. He was observed in hospital for 2 h, during which time he had mild hallucinations and could not move his limbs. [...] Clinically, the drug promotes emotional expression, a talkative uninhibited state (7), and visual and auditory sensory distortions (8). No other clinical studies appear in the medical literature. There are no reported pharmacological studies in humans. Some of the drug's physiological properties are also common to the recreational drug methylenedioxymethamphetamine (Ecstasy). Not surprisingly, 5-MeO-DIPT is a club drug (2) and has been substituted for Ecstasy on the street (3). [...] In 1980, Shulgin and Carter (7) described the administration of 5-MeO-DIPT to 10 human subjects. Each person received a 0.1mg oral dose which was then increased in increments of 30 to 50% in subsequent drug administrations. Threshold subjective effects were observed with a 4-mg dose. Effective doses were between 6 and 10 mg. The peak drug effect occurred at 1 to 1.5 h after ingestion, and recovery was observed after 3 h with no residual symptoms at 6 h. Subjects reported a relaxed feeling associated with emotional enhancement. They were frequently talkative and felt their conversations to be expressive and stimulating. Shulgin and Shulgin (8) later summarized the responses from an additional 10 human subjects upon administration of 6 to 12 mg of 5-MeO-DIPT. Most subjects reported auditory and visual distortions. Two indicated aphrodisiac tendencies; one experienced gastrointestinal emptying, muscle spasms, and agitation; and one indicated a synergistic effect with marijuana. [...] In our patient, the drug lasted 3.5 h. He said he felt "weird" (apprehensive) and saw symbols (visual hallucination) as opposed to being talkative or expressive of his emotions.
^abcdeCompton DM, Dietrich KL, Selinger MC, Testa EK (May 2011). "5-methoxy-N,N-di(iso)propyltryptamine hydrochloride (Foxy)-induced cognitive deficits in rat after exposure in adolescence".Physiol Behav.103 (2):203–209.doi:10.1016/j.physbeh.2011.01.021.PMID21295050.
^abDrug Enforcement Administration (Dea), Department of Justice (April 2003). "Schedules of controlled substances: temporary placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into Schedule I. Final rule".Fed Regist.68 (65):16427–16430.PMID12678045.
^abDrug Enforcement Administration (Dea), Department of Justice (September 2004). "Schedules of controlled substances: placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into schedule I of the Controlled Substances Act. Final rule".Fed Regist.69 (188):58950–58953.PMID15455477.
^abcNichols DE (April 2016)."Psychedelics"(PDF).Pharmacol Rev.68 (2):264–355.doi:10.1124/pr.115.011478.PMC4813425.PMID26841800.Ikeda et al. (2005) reported flashbacks after use of 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) by a 35-year-old man without a previous psychiatric history. He had used the substance six or seven times over 5 months but discontinued it after he had a bad trip, with anxiety, palpitations, auditory oversensitiveness, and visual distortions. Treatment with oral risperidone ameliorated his symptoms. [...] Fantegrossi et al. (2006) demonstrated that 5-MeODIPT induced the head twitch in mice, and the effect was antagonized by pretreatment with the 5-HT2A– selective antagonist M100907. The affinity of 5-MeO-DIPT was measured at rat 5-HT1A, 5-HT2A, and 5-HT2C receptors using antagonist radioligands, with Ki values determined to be 35 nM, 5620 nM, and 1700 nM, respectively. Thus, despite the higher affinity for 5-MeO-DIPT at the 5-HT1A receptor, the head twitch was mediated through the 5-HT2A receptor.
^Ikeda A, Sekiguchi K, Fujita K, Yamadera H, Koga Y (April 2005). "5-methoxy-N,N-diisopropyltryptamine-induced flashbacks".Am J Psychiatry.162 (4): 815.doi:10.1176/appi.ajp.162.4.815.PMID15800171.
^Smolinske SC, Rastogi R, Schenkel S (December 2005). "Foxy methoxy: a new drug of abuse".J Med Toxicol.1 (1):22–25.doi:10.1007/BF03160901.PMID18072099.
^Tanaka E, Kamata T, Katagi M, Tsuchihashi H, Honda K (November 2006). "A fatal poisoning with 5-methoxy-N,N-diisopropyltryptamine, Foxy".Forensic Science International.163 (1–2):152–154.doi:10.1016/j.forsciint.2005.11.026.PMID16406422.
^Alatrash G, Majhail NS, Pile JC (April 2006). "Rhabdomyolysis after ingestion of "foxy," a hallucinogenic tryptamine derivative".Mayo Clin Proc.81 (4):550–551.doi:10.4065/81.4.550.PMID16610577.
^Itokawa M, Iwata K, Takahashi M, Sugihara G, Sasaki T, Abe Y, Uno M, Hobo M, Jitoku D, Inoue K, Arai M, Yasuda I, Shintani M (April 2007). "Acute confusional state after designer tryptamine abuse".Psychiatry Clin Neurosci.61 (2):196–199.doi:10.1111/j.1440-1819.2007.01638.x.PMID17362440.
^"Kᵢ Database".PDSP. 26 March 2025. Retrieved26 March 2025.
^abcSogawa C, Sogawa N, Tagawa J, Fujino A, Ohyama K, Asanuma M, Funada M, Kitayama S (April 2007). "5-Methoxy-N,N-diisopropyltryptamine (Foxy), a selective and high affinity inhibitor of serotonin transporter".Toxicol Lett.170 (1):75–82.Bibcode:2007ToxL..170...75S.doi:10.1016/j.toxlet.2007.02.007.PMID17382495.
^abcdefNakagawa T, Kaneko S (January 2008). "Neuropsychotoxicity of abused drugs: molecular and neural mechanisms of neuropsychotoxicity induced by methamphetamine, 3,4-methylenedioxymethamphetamine (ecstasy), and 5-methoxy-N,N-diisopropyltryptamine (foxy)".J Pharmacol Sci.106 (1):2–8.doi:10.1254/jphs.fm0070141.PMID18198474.
^abcHalberstadt AL, Geyer MA (September 2011)."Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens".Neuropharmacology.61 (3):364–381.doi:10.1016/j.neuropharm.2011.01.017.PMC3110631.PMID21256140.Certain indolealkylamines, including DMT, N,N-dipropyltryptamine (DPT), 5-MeO-DMT, and 5-methoxy-N,Ndiisopropyltryptamine (5-MeO-DIPT) block 5-HT uptake at micromolar concentrations (Nagai et al., 2007; Sogawa et al., 2007; Cozzi et al., 2009) and serve as substrates for the 5-HT transporter (Cozzi et al., 2009). [...] Likewise, HTR induced by DPT, 5-MeO-DIPT, and TCB-2 in mice is blocked by M100,907 and MDL 11,939 (Fantegrossi et al., 2006, 2008; Fox et al., 2009). [...] Fantegrossi and colleagues have reported that the HTR induced by DOI, 2C-T-7, DPT, and 5-MeO-DIPT in NIH Swiss and Swiss-Webster mice typically follows an inverted U-shaped dose–response function (Fantegrossi et al., 2005, 2006, 2008, 2010).
^abLi K, Li N, Chen Y, Li X, Qiao Y, Wang D, Di B, Xu P (September 2025). "Effects of three tryptamines: alpha-methyltryptamine, 5-methoxy-alpha-methyltryptamine, and 5-methoxy- N , N -diisopropyltryptamine on acute toxicity, locomotor activity, and hallucinogenic behavior in mice".Behav Pharmacol.36 (6):429–437.doi:10.1097/FBP.0000000000000841.PMID40622300.
^Glennon RA, Young R, Jacyno JM, Slusher M, Rosecrans JA (January 1983). "DOM-stimulus generalization to LSD and other hallucinogenic indolealkylamines".Eur J Pharmacol.86 (3–4):453–459.doi:10.1016/0014-2999(83)90196-6.PMID6572591.
^Gołembiowska, Krystyna (2022). "Pharmacology and Neurotoxicity of 5-MeO-DIPT".Handbook of Neurotoxicity. Cham: Springer International Publishing. pp. 1403–1414.doi:10.1007/978-3-031-15080-7_207.ISBN978-3-031-15079-1.
^Compton DM, Selinger MC, Testa EK, Larkins KD (June 2006). "An examination of the effects of 5-Methoxy-n, n-di(ISO)propyltryptamine hydrochloride (Foxy) on cognitive development in rats".Psychol Rep.98 (3):651–661.doi:10.2466/pr0.98.3.651-661.PMID16933659.
^Noworyta-Sokołowska K, Górska AM, Gołembiowska K (October 2018). "The effect of repeated-intermittent exposure to 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) during adolescence on learning and memory in adult rats".Pharmacol Rep.70 (5):890–895.doi:10.1016/j.pharep.2018.04.001.PMID30096487.
^Meyer MR, Maurer HH (June 2010). "Metabolism of designer drugs of abuse: an updated review".Curr Drug Metab.11 (5):468–482.doi:10.2174/138920010791526042.PMID20540700.
^Kamata T, Katagi M, Kamata HT, Miki A, Shima N, Zaitsu K, Nishikawa M, Tanaka E, Honda K, Tsuchihashi H (February 2006). "Metabolism of the psychotomimetic tryptamine derivative 5-methoxy-N,N-diisopropyltryptamine in humans: identification and quantification of its urinary metabolites".Drug Metab Dispos.34 (2):281–287.doi:10.1124/dmd.105.005835.PMID16280455.
^Narimatsu S, Yonemoto R, Saito K, Takaya K, Kumamoto T, Ishikawa T, Asanuma M, Funada M, Kiryu K, Naito S, Yoshida Y, Yamamoto S, Hanioka N (April 2006). "Oxidative metabolism of 5-methoxy-N,N-diisopropyltryptamine (Foxy) by human liver microsomes and recombinant cytochrome P450 enzymes".Biochem Pharmacol.71 (9):1377–1385.doi:10.1016/j.bcp.2006.01.015.PMID16510126.
^abKuwahara T, Nakakura T, Oda S, Mori M, Uehira T, Okamoto G, Yoshino M, Sasakawa A, Yajima K, Umemoto A, Takada K, Makie T, Yamamoto Y (February 2008). "Problems in three Japanese drug users with Human Immunodeficiency Virus infection".J Med Invest.55 (1–2):156–160.doi:10.2152/jmi.55.156.PMID18319560.
^Togari T, Inoue Y, Takaku Y, Abe S, Hosokawa R, Itagaki T, Yoshizawa S, Oki S, Katakura N, Yamauchi A, Wakabayashi C, Yajima T (July 2016). "Recreational drug use and related social factors among HIV-positive men in Japan".AIDS Care.28 (7):932–940.doi:10.1080/09540121.2016.1140888.PMID26887351.
^"关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Archived fromthe original on 1 October 2015. Retrieved1 October 2015.
^"notisum.se"(PDF).Archived(PDF) from the original on 2013-09-29. Retrieved2013-09-06.
